From Ian DeMeritt, Senior Medical Writer, Palio In what may be the first DDMAC letter to focus on Facebook, Novartis Pharmaceuticals was just warned that its use of Share Widgets on the Tasigna (nilotinib) Web site was illegal and that it misbranded the drug. Tasigna is “indicated for the treatment of chronic phase and accelerated phase [...]
ShareEntries Tagged as 'advertising'
As Seen on TV… and in My House
July 21st, 2010 · No Comments · Creative, advertising
From Shelly Hagen, Copywriter, Palio Every now and then as I’m sitting watching a show with my boys, a commercial catches my attention. Not for the reason you might think – no, I don’t really want to purchase the Ped Egg foot care “system” or the Topsy Turvy tomato grower. More often than not, I [...]
ShareTags:Hanger Cascaders·infomercial·Little Giant Ladder·Ped Egg·Shake Weight·Sham-Wow·Slap Chop·Topsy Turvy·TV
The 60-Second Guide to Understanding DDMAC’s Guidance on Pre-Launch Communications
July 14th, 2010 · No Comments · Brand Planning, Industry Trends, advertising
From Geoffrey Sheldon, VP, Brand Planning Director, Palio One of the biggest factors in ensuring a successful launch of a new prescription drug lies in a marketer’s ability to generate pre-launch buzz and brand name awareness. Unfortunately, this is often easier said than done, due to restrictions by DDMAC on what can and can’t be [...]
ShareAdirondack
July 1st, 2010 · No Comments · Creative, advertising
From Philip Reynolds, Associate Creative Director, Palio There are two sides to Amtrak’s New York-to-Saratoga train, the Adirondack. If you’ve done it before, you know to get a seat on the “good” – west – side of the aisle, because that’s the side that affords you one of the most beautiful 3-hours of view I [...]
ShareTags:Adirondack·Alice Miller·Amtrack·Hudson·PowerPoint·research·Saratoga
“What’s up, doc?” The FDA Bad Ad Program wants to know.
May 28th, 2010 · 1 Comment · Medical Strategy, advertising
From Jim Mittler, Medical Director, PhD, Palio We’ve all seen bad drug advertisements – confusing concepts, poorly written or too much copy, disconnected visual elements, etc. The FDA is now stepping up their monitoring for bad ads, but not for the creative aspects or connection to the brand. (Although, in some cases I wish there [...]
ShareThe Beauty of the Line Extension
April 12th, 2010 · 3 Comments · Brand Planning, advertising
From Jon Hussey, SVP, Director of Brand Planning, Palio Don’t get me wrong, I love Gatorade. And by that, I mean that I love orange Gatorade, and sometimes drink red or yellow, or maybe purple when I am tired of orange. I am an avid cyclist, runner and triathlete, so I probably drink an average [...]
Share10 Ways to Ensure a Successful Agency-Client Relationship
March 1st, 2010 · No Comments · Account Services, advertising
From Mike Myers, President, Palio I’ve been asked over time by many clients, agency personnel and people representing media to describe the key elements of a successful agency-client relationship. Listed below are my top 10 “platform messages” on the subject. Originally put down on paper for an article in MedAd News in 2007, my current thoughts are outlined below [...]
ShareTags:advertising·Agency Partnership·Med Ad News·Mike Myers·PM360·Relationships
Anyone Ready Yet for an Evolved Approach to Agency Compensation?
February 15th, 2010 · No Comments · Industry Trends, advertising
From Mike Myers, President, Palio (@mmyerspalio) Last year, I had a breakfast meeting with James Chase (Editor in Chief of Medical Marketing & Media) and Scott Dattoli (Publisher). Over coffee and pastries, we discussed a range of topics with a broad objective of getting to know each other at some level. Near the end of [...]
ShareTags:advertising·agency compensation·Coca Cola·marketing·Mike Myers·Palio·Procter & Gamble
Lady Irina & FDA Warning Letters: What’s Really Going On?
February 5th, 2010 · 1 Comment · Industry Trends, advertising
Most marketers and brands live with a beleif that FDA involvement = bad. Marketing communications that take full advantage of a brand’s label = good. So, what happens when the big “bad” FDA comes calling when an ad or other promotional effort crosses that grey line?
ShareTags:advertising·FDA·marketing·Mike Myers·Palio·Warning Letters
